A team of researchers directed by Frédéric Coin, Inserm Research Director at the Institute of Genetics and Molecular and Cellular Biology (IGBMC) in Strasbourg (a Joint Inserm/CNRS/University of Strasbourg Research Unit), has discovered a new drug that inhibits repair: spironolactone, which seems ...
A team of French researchers, led by Dr. Anna Buj-Bello (Genethon/Inserm) and teams at the University of Washington and Harvard Medical School in the United States, have demonstrated the efficacy of gene therapy in models of myotubular myopathy, an extremely severe neuromuscular ...
A French and English team (AP-HP, Inserm, UPEC, CEA/Mircen, Oxford Biomedica, Cambridge University) has conducted a clinical phase 1/2 gene therapy study among patients suffering from an evolved form of Parkinson’s disease. Fifteen patients were able to benefit from this new treatment, ...
A phase I/II gene therapy clinical trial for children suffering from Sanfilippo B syndrome, a rare genetic disease, enrolled a first patient in October of this year. ...
Certain parts of DNA are highly mobile and their dynamic motion participates in controlling gene expression. The research team working under Maria‐Elena Torres‐Padilla, an Inserm research director at the Institute of Genetics and Molecular and Cellular Biology, has just developed a method ...
Teams from CNRS, the Université de Strasbourg and Inserm, led by Daniel Riveline1, Jean-Marie Lehn2 and Marie-France Carlier3, have synthesized molecules capable of causing rapid growth of actin networks, one of the components of the cytoskeleton. ...
Press release
14.12.2021
Press release
21.10.2021
06.12.2021
09.12.2021